A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Bacteria also defend themselves against pathogen attacks using mechanisms like those of the immune system. But if there is a ...

Valitor Inc. has presented preclinical results on VLTR-559, its long-acting anti-VEGF biologic candidate for durable wet age-related macular degeneration (AMD). VLTR-559, developed using Valitor’s ...

The Senate Appropriations Committee met July 31 to markup legislation that would fund the Department of Health and Human Services – including an additional $400 million for the National Institutes of ...

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...

The BioWorld Drug Developers Index (BDDI) rebounded in the second quarter, ending the first half (H1) of 2025 up 1.23% after ...

The U.S. FDA has cleared Actio Biosciences Inc.’s IND application and granted fast track designation to ABS-1230, an expected ...

Ultromics Ltd. raised $55 million in a series C financing round to expand its commercial footprint across the U.S. and invest in the development of new AI modules for earlier, more accurate detection ...

In a recent publication, researchers from The First Affiliated Hospital of Zhengzhou University (China) and collaborators investigated the association between phosphoglycerate kinase 1 (PGK1) ...

Beijing Tide Pharmaceutical Co. Ltd. has divulged nanobody-drug conjugates comprising a nanobody targeting B7 homolog 3 (B7-H3, CD276) covalently bound to exatecan through a linker reported to be ...

Investigators at Yonsei University have reported findings from studies conducted to identify small molecules capable of disaggregating amyloid-β42 (Aβ42) aggregates, a hallmark of Alzheimer’s disease.

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...